News Quantified

MRKR – marker therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]

Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]

Ladenburg Thalmann

Form 4 Marker Therapeutics, For: Dec 23 Filed by: ELMS STEVE

Form 4 Marker Therapeutics, For: Dec 23 Filed by: NEA Partners 16, L.P.

Form 8-K Marker Therapeutics, For: Dec 23

Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.

Form 8-K Marker Therapeutics, For: Dec 19

Top News Gainers

4/29 Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia 15.8%

8/15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs 15.0%

8/6 Marker Therapeutics Appoints Steve Elms to its Board of Directors 12.4%

4/10 FDA grants emergency authorization to two blood purification systems [MarketWatch] 10.9%

6/20 Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma 9.0%

5/9 Q1/2019 3/31/2019 EPS -0.120 ZacksConsensus N/A ActVsEst N/A - N/A 7.5%

3/2 Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million 6.7%

11/11 Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019 5.0%

8/8 Form 4 Marker Therapeutics, For: Aug 06 Filed by: ELMS STEVE 4.5%

8/13 TapImmune Inc. (NASDAQ: MRKR) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $16.00 price target on the stock. 4.4%

Top News Decliners

11/12 Form 10-Q Marker Therapeutics, For: Sep 30 -29.7%

7/19 Form 8-K Marker Therapeutics, For: Jul 19 -19.0%

3/12 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -16.8%

5/2 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. -8.2%

10/9 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth [Yahoo! Finance News] -6.5%

7/20 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR -5.8%

4/28 TapImmune Inc. (NASDAQ: MRKR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.7%

2/5 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.3%

2/11 Form 8-K Marker Therapeutics, For: Feb 11 -5.0%

4/21 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -5.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day